BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Securities Report
Sanofi India Ltd.’s Q3 CY20 reported a muted performance during the quarter.
Revenue declined 11.9% YoY to Rs 6.9 billion but the base includes business that has been divested along with the Ankleshwar plant.
Adjusting for it, approximate growth stood at 3.8% YoY. Ebitda margin improved 550 basis points YoY and 310 basis points QoQ to 28.0% with lower expenses.
Adjusted profit after tax declined 19.0% to Rs 1.3 billion.
As per All Indian Origin Chemists and Distributors Ltd.’s data, company reported a growth of 4.5% for the quarter.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR